Companies › MIBIO PTE.
1 active drug program in 1 registered trial: 1 Phase 3; Hematology; next expected readout Oct 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| rhTPO Recombinant human thrombopoietin (TPO) receptor agonist | THPO | Phase 3 | Thrombocytopenia Associated With Chronic Liver Disease | Oct 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07911800 | rhTPO | Phase 3 | Thrombocytopenia Associated With Chronic Liver Disease | Hematology | Oct 2028 |
Geropharm Sichuan Clover Biopharmaceuticals Chongqing Peg-Bio Biopharm
Pharmanutra Vega Therapeutics VarmX Bioverativ, a Sanofi company Hangzhou Gensciences Biopharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.